


## Mifamurtide

<b>Cat. No.:</b>	HY-13682
<b>CAS No.:</b>	83461-56-7
<b>Molecular Formula:</b>	C <sub>59</sub> H <sub>109</sub> N <sub>6</sub> O <sub>19</sub> P
<b>Molecular Weight:</b>	1237.5
<b>Target:</b>	NOD-like Receptor (NLR)
<b>Pathway:</b>	Immunology/Inflammation
<b>Storage:</b>	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (80.81 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	0.8081 mL	4.0404 mL	8.0808 mL
		5 mM	0.1616 mL	0.8081 mL	1.6162 mL
	10 mM	0.0808 mL	0.4040 mL	0.8081 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (2.02 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	NOD2
<b>In Vitro</b>	Mifamurtide (MTP-PE; 100 μM) induces a reduction of MG63 cells number when co-cultured with macrophages <sup>[3]</sup> . Mifamurtide (100 μM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide increases the iron transporter

DMT1 protein<sup>[3]</sup>.

L-mifamurtide (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo<sup>[1]</sup>.

Mifamurtide acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Mifamurtide (MTP-PE; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination<sup>[1]</sup>.

Mifamurtide (50  $\mu$ g/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide (equivalent to 20  $\mu$ g MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, BALB/c mice with KHOS osteosarcoma cells <sup>[1]</sup>
Dosage:	1 mg/kg
Administration:	IV; twice per week for 4 weeks
Result:	Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

## CUSTOMER VALIDATION

- The Ohio State University. 2023 Apr.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.
- [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripectide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.
- [3]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.
- [4]. Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11(7):687-698.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA